反刍动物疫苗市场 - 全球产业规模、份额、趋势、机会及预测（按动物类型、疫苗类型、疫苗适应症、给药途径、地区和竞争格局划分，2021-2031年）

全球反刍动物疫苗市场预计将从 2025 年的 39.1 亿美元成长到 2031 年的 53.2 亿美元，复合年增长率为 5.27%。

这些生物製药旨在诱导绵羊、山羊和牛等草食性哺乳动物产生适应性免疫，作为抵抗感染疾病的主要防线。该行业的主要驱动力是全球对动物性蛋白质日益增长的需求，这要求畜牧业的健康和生产力达到高标准，以确保粮食安全。此外，各国政府严格的跨境疾病根除计画以及对遏制通用感染疾病传播的日益重视，也是市场接受度的重要支柱。这些驱动因素独立于技术变革而存在，从而在现代畜牧管理中催生了对全面免疫策略的根本且不可或缺的需求。

然而，市场面临着许多障碍，因为新型疫苗的商业化规模化生产需要大量的资金投入和监管负担。应对病毒变异株所需的复杂研究也需要巨额资金，这往往阻碍了小规模的企业进入市场。 AnimalhealthEurope的报告凸显了这种资本密集的特点：2023年，动物用药品产业将约8%的总销售额用于研发。这种高成本结构常常导致新产品上市延迟，并可能阻碍对价格敏感的发展中地区的市场成长。

市场驱动因素

全球反刍动物疫苗市场的主要驱动力是全球对乳製品和动物性蛋白质需求的不断增长。随着新兴经济体都市化的推进和可支配收入的增加，人们的饮食结构发生改变，畜牧养殖户正增加生产力以满足不断增长的牛肉、牛奶和羊肉消费需求。这种扩张需要严格的畜群健康管理，而疫苗接种已成为降低死亡率和优化生产效率的重要预防措施。保障粮食供应的经济压力迫使养殖户实施针对地方性病原体和新发病原体的预防性免疫策略，以维持稳定的生产。例如，经合组织-粮农组织于2024年7月发布的《2024-2033年农业展望》预测，到2033年，全球羊肉消费量将增加16%，凸显了永续畜群扩张和健康维护的必要性。

同时，跨境和通用感染疾病的日益频繁加速了先进免疫疗法的迫切应用。严重感染疾病（如口蹄疫和蓝舌病）的爆发威胁畜牧业资产并扰乱国际贸易，迫使各国政府实施严格的疫苗接种强制措施。气候变迁进一步加剧了这些风险，促进了病媒的传播，因此需要迅速采取药物干预措施来阻止病毒传播。例如，2024年9月，英国环境、食品和农村事务部宣布，英国确诊的蓝舌病毒（BTV-3）病例已达82例，显示疾病管制措施迫在眉睫。这种不稳定的疾病情况支撑着该行业的财务表现。 2024年2月，硕腾公司宣布其2023财年畜牧业业务的营业收入成长了6%，这显示该公司持续依赖兽医保护措施。

市场挑战

全球反刍动物疫苗市场的发展受到疫苗研发高额资金需求和严格法规环境的显着限制。开发针对不断演变的病毒株的有效疫苗需要耗费大量时间和金钱进行广泛的研究。这种高准入门槛尤其影响那些拥有创新平台但缺乏资金进行漫长临床试验和核准流程的中小型生物技术公司。因此，市场日益集中于少数主要企业，削弱了通常推动快速创新和降低价格的竞争压力。

这种沉重的经济负担直接限制了对成本敏感的市场中价格适中的疫苗供应。将单一产品推向市场所需的巨额投资迫使製造商将重点放在高利润地区，往往忽略了反刍动物健康对其生计至关重要的开发中国家。例如，根据欧洲动物健康协会（AnimalhealthEurope）的数据显示，2024年兽医保健产业在研发方面的投资超过6.49亿美元。这些巨额的营运成本延缓了新疫苗的商业化进程，限制了该行业快速应对新出现的跨境疾病的能力，并造成了阻碍其拓展全球市场的瓶颈。

市场趋势

市场正在加速采用mRNA和DNA疫苗平台，与传统免疫疗法相比，这些平台具有更高的速度和柔软性。这项技术进步使製造商能够快速设计非复製型抗原来对抗新出现的病毒株，同时避免生产灭活疫苗或减毒活病毒疫苗所需的漫长前置作业时间。这些平台对于控制威胁贸易连续性和牲畜群稳定的重大疫情至关重要。例如，2024年8月，美国农业部（USDA）核准了首个针对H5N1病毒的非活性、非复製型牛疫苗的田间试验，这标誌着先进生物技术在反刍动物健康管理应用方面迈出了重要一步。

同时，在全球对抗菌素抗药性（AMR）日益关注的背景下，畜牧业正致力于将疫苗深度融入抗生素减量策略。监管机构和供应链相关人员敦促畜牧生产者从被动的抗菌治疗转向预防性免疫通讯协定，从根本上重塑畜群健康管理。这项策略转变旨在减少重要药物的整体使用量，同时确保动物福利和生产力。为了支持这些预防措施的成功，英国兽药协会在其2024年11月发布的《英国兽医抗生素抗药性策略2023》（UK-VARSS 2023）文件中指出，2023年肉类用动物高优先级抗生素（HP-CIA）的销售量已降至0.11毫克/公斤。这反映出人们越来越依赖疫苗接种来抑制对抗生素的依赖。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球反刍动物疫苗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依动物种类（牛、羊和山羊）
  • 依疫苗类型（减毒活病毒疫苗、不活化疫苗、其他）
  • 疫苗适应症（牛病毒性腹泻感染疾病、牛呼吸道疾病、钩端螺旋体病、梭状菌感染、腹泻/牛腹泻、口蹄疫、其他）
  • 给药途径（注射、鼻腔给药）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美反刍动物疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲反刍动物疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区反刍动物疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲反刍动物疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美反刍动物疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球反刍动物疫苗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Boehringer Ingelheim International GmbH
• Zoetis Services LLC
• Vaxxinova International BV
• Merck & Co., Inc.
• Bimeda Animal Health Ltd.
• Indian Immunologicals Ltd.
• Elanco Animal Health Incorporated
• Virbac
• Ceva Sante Animale
• CZ Vaccines SAU

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Ruminant Vaccines Market is projected to expand from a valuation of USD 3.91 Billion in 2025 to USD 5.32 Billion by 2031, achieving a CAGR of 5.27%. These biological formulations are designed to induce acquired immunity in herbivorous mammals, such as sheep, goats, and cattle, serving as a primary defense against infectious diseases. The industry is chiefly driven by the growing global requirement for animal-based protein, which demands elevated standards of herd health and productivity to maintain food security. Furthermore, strictly enforced government eradication schemes for transboundary diseases and a sharpened focus on curbing zoonotic transmission act as foundational pillars for market adoption. These drivers operate independently of technological shifts, creating a fundamental baseline need for comprehensive immunization strategies in modern livestock operations.

Conversely, the market encounters substantial obstacles stemming from the heavy capital and regulatory loads required to scale new inoculants commercially. The intricate research necessary to tackle mutating viral strains demands vast financial resources, which often bars entry for smaller organizations. Highlighting this financial intensity, AnimalhealthEurope reported that in 2023, the animal health sector allocated roughly 8% of its total turnover to research and development. This elevated cost structure frequently delays the introduction of novel products, potentially hindering market growth in price-sensitive developing regions.

Market Driver

A primary engine for the Global Ruminant Vaccines Market is the escalating worldwide demand for dairy products and animal-derived protein. As urbanization and rising disposable incomes in emerging economies prompt dietary changes, livestock producers are intensifying operations to satisfy the growing consumption of beef, milk, and sheep meat. This production ramp-up necessitates stringent herd health management, making vaccination a vital preventive tool to reduce mortality rates and optimize efficiency. Economic imperatives to guarantee food supplies force farmers to implement prophylactic immunization strategies against both endemic and novel pathogens to ensure consistent output. For example, the OECD-FAO Agricultural Outlook 2024-2033, published in July 2024, forecasts a 16% rise in global sheep meat consumption by 2033, highlighting the need for sustained herd expansion and health maintenance.

At the same time, the increasing frequency of transboundary and zoonotic animal diseases is accelerating the urgent adoption of advanced immunotherapeutics. Outbreaks of severe viral infections like Foot and Mouth Disease (FMD) and Bluetongue threaten livestock assets and disrupt international trade, compelling governments to impose strict vaccination mandates. Climate variations further facilitate vector spread, heightening these risks and requiring swift pharmaceutical interventions to halt viral transmission. For instance, the Department for Environment, Food & Rural Affairs noted in September 2024 that confirmed Bluetongue virus (BTV-3) cases in the UK's current outbreak hit 82, indicating a critical need for disease control measures. This volatile disease landscape supports financial performance in the sector; Zoetis announced in February 2024 that its livestock portfolio saw 6% operational revenue growth in fiscal 2023, demonstrating the persistent dependence on veterinary safeguards.

Market Challenge

The progression of the Global Ruminant Vaccines Market is notably constrained by high capital requirements and rigorous regulatory environments linked to vaccine development. Formulating effective immunizations for evolving viral strains requires extensive research pathways that deplete significant time and financial resources. This steep barrier to entry disproportionately affects smaller biotechnology firms, which may possess innovative platforms but lack the funding to navigate prolonged clinical trials and approval processes. Consequently, the market sees a consolidation of influence among a few major entities, diminishing the competitive pressures that typically spur rapid innovation and price reductions.

This financial burden directly curtails the availability of affordable vaccines in cost-conscious markets. The massive investment needed to launch a single product compels manufacturers to focus on high-margin regions, often overlooking developing nations where ruminant health is essential for subsistence. Demonstrating the magnitude of these costs, AnimalhealthEurope stated that in 2024, the animal medicines industry invested over USD 649 million in research and development. Such immense overheads slow the commercialization of novel vaccines and restrict the industry's capacity to react quickly to emerging transboundary diseases, creating a bottleneck that stifles broader global market expansion.

Market Trends

The market is increasingly characterized by the accelerated uptake of mRNA and DNA vaccine platforms, which offer greater speed and flexibility compared to traditional immunologics. This technological evolution enables manufacturers to rapidly engineer non-replicating antigens to fight novel viral strains, avoiding the long lead times associated with inactivated or live-attenuated vaccine production. Such platforms are becoming essential for managing high-consequence outbreaks that threaten trade continuity and herd stability. Exemplifying this innovation, the U.S. Department of Agriculture (USDA) authorized the first field trial of a nonviable, non-replicating vaccine for cattle against the H5N1 virus in August 2024, marking a key milestone in applying advanced biotechnologies to ruminant health.

Concurrently, the industry is witnessing the robust integration of vaccines into antibiotic-reduction strategies, driven by intensifying global scrutiny over antimicrobial resistance (AMR). Regulatory bodies and supply chain stakeholders are compelling livestock producers to shift from reactive antibiotic treatments to proactive immunization protocols, fundamentally reshaping herd health management. This strategic pivot aims to lower the aggregate use of medically important drugs while safeguarding animal welfare and productivity. Underscoring the success of these preventive measures, the UK Veterinary Medicines Directorate reported in November 2024, within its 'UK-VARSS 2023' document, that sales of Highest Priority Critically Important Antibiotics (HP-CIAs) in food-producing animals dropped to 0.11 mg/kg in 2023, reflecting the sector's growing reliance on vaccination to curb antimicrobial dependency.

Key Market Players

• Boehringer Ingelheim International GmbH
• Zoetis Services LLC
• Vaxxinova International BV
• Merck & Co., Inc.
• Bimeda Animal Health Ltd.
• Indian Immunologicals Ltd.
• Elanco Animal Health Incorporated
• Virbac
• Ceva Sante Animale
• CZ Vaccines S.A.U.

Report Scope

In this report, the Global Ruminant Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ruminant Vaccines Market, By Animal Type

• Cattle
• Sheep & Goats

Ruminant Vaccines Market, By Vaccine Type

• Modified/ Attenuated Live
• Inactivated (Killed)
• Others

Ruminant Vaccines Market, By Vaccines Indication

• BVD Infection
• Bovine Respiratory Diseases (BRD)
• Leptospirosis
• Clostridial diseases
• Diarrhea/ Scours
• FMD
• Others

Ruminant Vaccines Market, By Route of Administration

• Injectable
• Intranasal

Ruminant Vaccines Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ruminant Vaccines Market.

Available Customizations:

Global Ruminant Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Ruminant Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Animal Type (Cattle, Sheep & Goats)
  • 5.2.2. By Vaccine Type (Modified/ Attenuated Live, Inactivated (Killed), Others)
  • 5.2.3. By Vaccines Indication (BVD Infection, Bovine Respiratory Diseases (BRD), Leptospirosis, Clostridial diseases, Diarrhea/ Scours, FMD, Others)
  • 5.2.4. By Route of Administration (Injectable, Intranasal)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Ruminant Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Animal Type
  • 6.2.2. By Vaccine Type
  • 6.2.3. By Vaccines Indication
  • 6.2.4. By Route of Administration
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Ruminant Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Animal Type
      • 6.3.1.2.2. By Vaccine Type
      • 6.3.1.2.3. By Vaccines Indication
      • 6.3.1.2.4. By Route of Administration
  • 6.3.2. Canada Ruminant Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Animal Type
      • 6.3.2.2.2. By Vaccine Type
      • 6.3.2.2.3. By Vaccines Indication
      • 6.3.2.2.4. By Route of Administration
  • 6.3.3. Mexico Ruminant Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Animal Type
      • 6.3.3.2.2. By Vaccine Type
      • 6.3.3.2.3. By Vaccines Indication
      • 6.3.3.2.4. By Route of Administration

7. Europe Ruminant Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Animal Type
  • 7.2.2. By Vaccine Type
  • 7.2.3. By Vaccines Indication
  • 7.2.4. By Route of Administration
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Ruminant Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Animal Type
      • 7.3.1.2.2. By Vaccine Type
      • 7.3.1.2.3. By Vaccines Indication
      • 7.3.1.2.4. By Route of Administration
  • 7.3.2. France Ruminant Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Animal Type
      • 7.3.2.2.2. By Vaccine Type
      • 7.3.2.2.3. By Vaccines Indication
      • 7.3.2.2.4. By Route of Administration
  • 7.3.3. United Kingdom Ruminant Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Animal Type
      • 7.3.3.2.2. By Vaccine Type
      • 7.3.3.2.3. By Vaccines Indication
      • 7.3.3.2.4. By Route of Administration
  • 7.3.4. Italy Ruminant Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Animal Type
      • 7.3.4.2.2. By Vaccine Type
      • 7.3.4.2.3. By Vaccines Indication
      • 7.3.4.2.4. By Route of Administration
  • 7.3.5. Spain Ruminant Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Animal Type
      • 7.3.5.2.2. By Vaccine Type
      • 7.3.5.2.3. By Vaccines Indication
      • 7.3.5.2.4. By Route of Administration

8. Asia Pacific Ruminant Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Animal Type
  • 8.2.2. By Vaccine Type
  • 8.2.3. By Vaccines Indication
  • 8.2.4. By Route of Administration
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Ruminant Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Animal Type
      • 8.3.1.2.2. By Vaccine Type
      • 8.3.1.2.3. By Vaccines Indication
      • 8.3.1.2.4. By Route of Administration
  • 8.3.2. India Ruminant Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Animal Type
      • 8.3.2.2.2. By Vaccine Type
      • 8.3.2.2.3. By Vaccines Indication
      • 8.3.2.2.4. By Route of Administration
  • 8.3.3. Japan Ruminant Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Animal Type
      • 8.3.3.2.2. By Vaccine Type
      • 8.3.3.2.3. By Vaccines Indication
      • 8.3.3.2.4. By Route of Administration
  • 8.3.4. South Korea Ruminant Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Animal Type
      • 8.3.4.2.2. By Vaccine Type
      • 8.3.4.2.3. By Vaccines Indication
      • 8.3.4.2.4. By Route of Administration
  • 8.3.5. Australia Ruminant Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Animal Type
      • 8.3.5.2.2. By Vaccine Type
      • 8.3.5.2.3. By Vaccines Indication
      • 8.3.5.2.4. By Route of Administration

9. Middle East & Africa Ruminant Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Animal Type
  • 9.2.2. By Vaccine Type
  • 9.2.3. By Vaccines Indication
  • 9.2.4. By Route of Administration
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Ruminant Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Animal Type
      • 9.3.1.2.2. By Vaccine Type
      • 9.3.1.2.3. By Vaccines Indication
      • 9.3.1.2.4. By Route of Administration
  • 9.3.2. UAE Ruminant Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Animal Type
      • 9.3.2.2.2. By Vaccine Type
      • 9.3.2.2.3. By Vaccines Indication
      • 9.3.2.2.4. By Route of Administration
  • 9.3.3. South Africa Ruminant Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Animal Type
      • 9.3.3.2.2. By Vaccine Type
      • 9.3.3.2.3. By Vaccines Indication
      • 9.3.3.2.4. By Route of Administration

10. South America Ruminant Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Animal Type
  • 10.2.2. By Vaccine Type
  • 10.2.3. By Vaccines Indication
  • 10.2.4. By Route of Administration
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Ruminant Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Animal Type
      • 10.3.1.2.2. By Vaccine Type
      • 10.3.1.2.3. By Vaccines Indication
      • 10.3.1.2.4. By Route of Administration
  • 10.3.2. Colombia Ruminant Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Animal Type
      • 10.3.2.2.2. By Vaccine Type
      • 10.3.2.2.3. By Vaccines Indication
      • 10.3.2.2.4. By Route of Administration
  • 10.3.3. Argentina Ruminant Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Animal Type
      • 10.3.3.2.2. By Vaccine Type
      • 10.3.3.2.3. By Vaccines Indication
      • 10.3.3.2.4. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Ruminant Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Boehringer Ingelheim International GmbH
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Zoetis Services LLC
• 15.3. Vaxxinova International BV
• 15.4. Merck & Co., Inc.
• 15.5. Bimeda Animal Health Ltd.
• 15.6. Indian Immunologicals Ltd.
• 15.7. Elanco Animal Health Incorporated
• 15.8. Virbac
• 15.9. Ceva Sante Animale
• 15.10. CZ Vaccines S.A.U.

16. Strategic Recommendations

17. About Us & Disclaimer